Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessPublished version of a preprint
The DOI matches its Crossref record; 331 of the 348 references it cites were found in a registry or an index; 216 of the 381 sources its claims cite were checked for support.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
Overview
CoChat Summary
TL;DR
This 2022 ADA/EASD consensus report updates person-centered management of hyperglycemia in nonpregnant adults with type 2 diabetes, emphasizing holistic care, weight management, physical activity, DSMES, and individualized medication selection. It gives strongest priority to GLP-1 receptor agonists and SGLT2 inhibitors for people with established or high-risk cardiovascular, kidney, or heart failure disease, based on evidence synthesized from trials and meta-analyses published through 13 June 2022.
Key findings
- A PubMed search identified randomized controlled trials, systematic reviews, and meta-analyses published in English between 28 January 2018 and 13 June 2022; the report built on the 2012, 2015, 2018, and 2019 consensus statements.
- In a network meta-analysis of 453 trials across nine drug classes, the greatest HbA1c reductions were seen with insulin regimens and GLP-1 RA; subcutaneous semaglutide had the greatest body-weight reduction, and SGLT2i and GLP-1 RA had the greatest blood-pressure reductions.
- In comparative effectiveness analyses, SGLT2i were superior to GLP-1 RA for reducing heart failure hospitalization and a composite kidney outcome, while GLP-1 RA appeared more efficacious for stroke; no important differences were evident for mortality or other cardiovascular outcomes.
- The report states that DSMES significantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective; it also reports specific trial effects such as STEP 2 weight loss of 9.6% with semaglutide 2.4 mg, and AWARD-11 and SUSTAIN FORTE showing greater HbA1c and weight reductions with higher-dose GLP-1 RA.
Methods
- Consensus report written by an ADA/EASD panel, using prior consensus reports as the starting point and incorporating evidence from publications since 2018.
- Evidence source: PubMed search for English-language RCTs, systematic reviews, and meta-analyses published between 28 January 2018 and 13 June 2022, plus reference-list screening for additional studies.
- Evidence appraisal: papers were grouped by topic, subgroup meta-analyses were assessed for credibility using relevant guidance, and recommendations were informed by GRADE; draft recommendations were reviewed by invited reviewers and opened for public comment.
Limitations
- The paper states that subgroup analyses should not be regarded as conclusive and should be formally appraised and ideally complemented by relevant RCTs.
- The text notes that evidence is limited for some populations because of underrepresentation in trials, including younger people, older adults, women, and non-White participants; this is an evident limitation of generalizability.
- The report also makes evident that some conclusions rely on network meta-analyses, observational data, and nonrandomized studies, and that some outcomes (e.g., long-term cardiovascular profile of tirzepatide) were still pending, which limits certainty.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
140 Valid · 9 Not valid · 61 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
What the sources say
- Not checked — no full text of the sourcecites [223] Tsapas, 2020, Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis, Ann Intern Med source
- Disputedcites [259] Palmer, 2021, Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ sourceExperimental — accuracy not yet measured
The Results > Outcomes section reports fewer non-fatal myocardial infarctions with both drug classes in low-risk patients and fewer non-fatal strokes with GLP-1 receptor agonists. That contradicts the claim that no drug class benefits cardiovascular events in this group. The Discussion > Clinical uncertainties section cautions that trials generally did not include the lowest-risk patients and does not judge whether the absolute effects are clinically notable. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“As with any laboratory test, HbA1c measurement has limitations (2,52).”
What the sources say
- Supportedcites [2] Draznin, 2022, 6. Glycemic targets: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The “A1C Limitations” section (p. 2) explicitly says the A1C test is subject to limitations and that its measurement varies, as with any laboratory test. (LLM, conf=0.95)
- Supportedcites [52] American Diabetes Association Professional Practice Committee, 2022, 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The Fasting and 2-Hour Plasma Glucose section explicitly refers to “these limitations with A1C,” including lower diagnostic sensitivity and imperfect correlation with average glucose in some individuals. The Race/Ethnicity/Hemoglobinopathies section also notes that hemoglobin variants can interfere with A1C measurement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, these multifaceted domains (heterogeneity across individual characteristics, social determinants of health, and psychosocial factors) challenge individuals with diabetes, their families, and their providers when attempting to integrate diabetes care into daily life (49).”
What the sources say
- Supportedcites [49] Young-Hyman, 2016, Psychosocial care for people with diabetes: a position statement of the American Diabetes Association, Diabetes Care source
The Introduction says complex environmental, social, behavioral, and emotional factors challenge people with diabetes and their families as they integrate care into daily life. Life Course Considerations identifies social determinants and person-based characteristics as factors providers should consider, while the Conclusions describes challenges to providing that care. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Type 2 diabetes is a very heterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40).”
What the sources say
- Supportedcites [39] Ahlqvist, 2018, Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, Lancet Diabetes Endocrinol source
The Abstract describes type 2 diabetes as highly heterogeneous and identifies age at diagnosis, BMI, and insulin resistance as clustering variables. It reports that the resulting clusters differed in patient characteristics and risk of complications, supporting the claimed variation. (LLM, conf=0.92)
- Supportedcites [40] Pigeyre, 2022, Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial, Diabetologia source
The Introduction describes heterogeneity in diabetes presentation and progression. The Results identify subgroups differing in age at diagnosis, BMI and insulin-resistance-related characteristics; the Abstract reports differences in renal outcomes between subgroups. Together, these passages support the cited statement about variation among people with type 2 diabetes. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High-quality evidence has consistently shown that DSMES signi fi cantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective (22,25 -30).”
What the sources say
- Not checked — no full text of the sourcecites [22] Draznin, 2022, 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes–2022, Diabetes Care source
- Partly supportedcites [25] Chrvala, 2016, Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control, Patient Educ Couns sourceExperimental — accuracy not yet measured
The Introduction says evidence from randomized and observational studies suggests DSME is cost-effective. The citing sentence presents cost-effectiveness as a consistently demonstrated finding, whereas this review does not establish it; Practical implications says DSME must be cost-effective, not that the review found it to be so. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [26] Pillay, 2015, Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis, Ann Intern Med source
- Not checked — no full text of the sourcecites [27] Zhao, 2017, Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, J Adv Nurs source
- Partly supportedcites [28] Odgers-Jewell, 2017, Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression, Diabet Med sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says group-based education for people with type 2 diabetes may be more cost-effective than individual education because it requires less time and funding. That qualified comparison does not establish the broader, unqualified claim that DSMES is cost-effective. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [29] He, 2017, Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis, Endocrine source
- Not checked — no full text of the sourcecites [30] Chatterjee, 2018, Diabetes structured self-management education programmes: a narrative review and current innovations, Lancet Diabetes Endocrinol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
127 more claims · 71 with their cited sources checked
Create a free account to see all 237 claims and every source verdict.
- It may state two separate claims as one. 88
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DiRECT dietary intervention was highly costeffective and deliverable in primary care. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“thus cost-savings might be greater. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may be particularly important in young-onset T2D where higher rates of obesity, more rapid deterioration in blood glucose levels and earlier development of diabetes complications have been observed [9,95].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increase insulin secretion regardless of glycemia, typically resulting in 2–3 kg weight gain [44].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [44]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Decision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 20×
“Notably, the benefits of GLP-1 RA and SGLT2i for cardiovascular and renal outcomes have been found to be independent of metformin use, and thus these agents should be considered in people with established or high risk of CVD, HF, or CKD, independent of metformin use (173–175).”
BackgroundInfluential
Research works printed but not linked: 2
- Nathan, Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study, N Engl J Med
- Nathan, Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes, N Engl J Med
Cited by
Items 301–400 of 2,053
Diabetic Peripheral Neuropathy: New Diagnostics and Treatment Perspectives
Dubský, M., Sojáková, D., Fejfarová, V., & Jude, E. B. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01267-5 · Cited by 29
“In people with T2D, this examination is conducted at diagnosis of T2D, whereas for T1D, it should be performed after 5 years and then in both groups annually [22].”
Alhagawy, A. J., Yafei, S., Hummadi, A. A., Abutaleb, R., Hakamy, M., Alzughbi, T., Gharawi, N., Moafa, M., Mokali, A., Alhiqwy, I., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192416794 · Cited by 17
“Worldwide, the prevalence of uncontrolled diabetes is still high despite improvement in treatment modalities and clear guidelines recommending treatment intensification [2].”
BackgroundMethodInfluentialFrías, J. P. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2184796 · Cited by 19
“In the recently published joint American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) Consensus Report on the management of hyperglycemia in T2D, GLP-1 RAs with proven cardiovascular benefits are recommended as first-line or add-on therapy in patients with preexisting or high ri…”
BackgroundBardram, J. E., Cramer-Petersen, C. L., Maxhuni, A., Christensen, M. V. S., Bækgaard, P., Persson, D. R., Lind, N., Christensen, M. B., Nørgaard, K., Khakurel, J., et al. (2023) · ACM Transactions on Computing for Healthcare · doi:10.1145/3586579 · Cited by 22
“There are multiple therapeutic options available for the treatment of T2D, including lifestyle interventions (physical activity and diet), oral antidiabetic medications, basal insulin therapy, and intensiied insulin therapy, depending on the severity of the disease [19].”
BackgroundAlkandari, A., Vaucher, J., & Marques-Vidal, P. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003377 · Cited by 15
Kurtzhals, P., Kreiner, F. F., & Bindra, R. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110881 · Cited by 22
Jhuo, J.-Y., Tong, Z.-J., Ku, P.-H., Cheng, H.-W., & Wang, H. (2023) · Environmental Pollution · doi:10.1016/j.envpol.2023.122380 · Cited by 17
Olsen, T. A., Beall, R. F., Knox, R. P., Tu, S. S., Kesselheim, A. S., & Feldman, W. B. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004309 · Cited by 20
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad285 · Cited by 18
Contemporary Clinical Perspectives on Targeting Remission of Type 2 Diabetes
Retnakaran, R. R., Kashyap, S. R., Gerstein, H. C., & Aroda, V. R. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad746 · Cited by 19
Self-citationMechanism and therapeutic targets of circulating immune cells in diabetic retinopathy
Zhao, B., Zhao, Y., & Sun, X. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107505 · Cited by 21
Jhu, J., Fang, Y., Huang, C., Liou, H., Chen, M., & Tsai, M. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14361 · Cited by 19
“…disease (ASCVD) or multiple cardiovascular risk factors, the 2022 consensus report from the American Diabetes Association and the European Association for the Study of Diabetes recommends a combination of GLP-1 RA and SGLT2i when HbA1c targets are unmet with monotherapy from either class 29 .”
Sun, Y., Lin, X., Zou, Z., Zhao, C., Liu, A., Zhou, J. W., Li, Z., Wu, X., Dou, S., Zhu, J., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02619-6 · Cited by 19
“T2DM is a complex metabolic disorder associated with various conditions, including cardiovascular disease [33], nonalcoholic fatty liver disease [34], and cancer [35].”
Chen, S., Pan, H., Huan, P., Wang, S., Sun, L., Ning, D., Ma, T., & Zhuang, Y. (2025) · Food Research International · doi:10.1016/j.foodres.2025.116487 · Cited by 15
Re-evaluating the concept of remission in type 2 diabetes: a call for patient-centric approaches
Khunti, K., Papamargaritis, D., Aroda, V. R., Anjana, R. M., & Kashyap, S. R. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00134-2 · Cited by 22
Self-citationDigital twin paradigm in diabetes prediction and management
Olawade, D. B., Owhonda, R. C., Alabi, J. O., Egbon, E., Daniel, R. I. A., & Bello, O. J. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.113075 · Cited by 25
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 35
Buse, J. B., Christensen, H. N., Harty, B. J., Mitchell, J., Soule, B. P., Zacherle, E. W., Cziraky, M. J., & Willey, V. J. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003206 · Cited by 21
Self-citationShi, C., Wan, Y., He, A., Wu, X., Shen, X., Zhu, X., Yang, J., & Zhou, Y. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02094-z · Cited by 17
Soares, A. L. D. S., Machado‐Lima, A., Brech, G. C., Greve, J. M. D., dos Santos, J. R., Inojossa, T. R., Rogero, M. M., Salles, J. E. N., Santarem-Sobrinho, J. M., Davis, C. L., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20105891 · Cited by 26
“Moreover, in the present study, the values of HbA1c were 7.2 (+/−1.1) for the PG and 7.0 (+/−1.2) for the CG, which were within the recommended range for people living with T2DM, according to the American College of Physicians [35].”
BackgroundMethodInfluentialPerspectives on weight control in diabetes – Tirzepatide
Várkonyi, T. T., Pósa, A., Pávó, N., & Pavo, I. J. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110770 · Cited by 23
“Metformin is the first-line glucose-lowering medication recommended by most international guidelines [26] and among other mechanisms of action, inhibits”
BackgroundCarlsson, K. S., Faurby, M. D., Nilsson, K., & Wolden, M. L. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01430-4 · Cited by 15
“The results of this study were presented in part at the 58th European Association for the Study of Diabetes Annual Meeting, 19–23 September 2022, Stockholm, Sweden.”
BackgroundChallenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin
MacIsaac, R. J., Deed, G., dʼEmden, M. C., Ekinci, E. I., HOCKING, S. L., Sumithran, P., & Rasalam, R. R. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01475-5 · Cited by 17
“Indeed, the American Diabetes Association/European Association for the Study of Diabetes (ADA/ EASD) updated their 2022 consensus statement for T2D to include tirzepatide [4].”
BackgroundInfluentialOnce-weekly Insulin Icodec as Compared to Once-daily Basal Insulins: A Meta-analysis
Mukhopadhyay, P., Chatterjee, P., Pandit, K., Sanyal, D., & Ghosh, S. K. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.11.004 · Cited by 16
Karagiannis, T., Τσάπας, Α., Bekiari, E., Toulis, K. A., & Nauck, M. A. (2024) · Diabetes Care · doi:10.2337/dc23-0925 · Cited by 17
The current landscape for diabetes treatment: Preventing diabetes-associated CV risk
Dardano, A., Bianchi, C., Garofolo, M., & Prato, S. D. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117560 · Cited by 18
Self-citationEmad-Eldin, M., Balata, G. F., el-Shorbagy, E., Hamed, M. S., & Attia, M. S. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i5.828 · Cited by 31
Reframing Chronicity with Urgency in Chronic Kidney Disease Management
Neuen, B. L., Tuttle, K. R., Bakris, G. L., & Vaduganathan, M. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000526 · Cited by 16
Engström, A., Söderling, J. K., Hviid, A. P., Eliasson, B., Guðbjörnsdóttir, S., Wintzell, V., Hveem, K., Jonasson, C., Melbye, M., Pasternak, B., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae045 · Cited by 22
GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis
Grenet, G., Ribault, S., Nguyen, G. B., Glais, F., Metge, A., Linet, T., Kassaï, B., Cornu, C., Bejan‐Angoulvant, T., Erpeldinger, S., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217701 · Cited by 18
Diabetes mellitus therapy in the light of oxidative stress and cardiovascular complications
Osman, A. A. M., Seres, A. B., & Ducza, E. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108941 · Cited by 21
Age at Menopause and Development of Type 2 Diabetes in Korea
Ko, B., Jung, J.-H., Han, K., & Nam, G. E. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.55388 · Cited by 17
Role of Diabetes Self-management Education for Our Health Systems and Economy
Hatipoğlu, B., & Pronovost, P. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae913 · Cited by 21
Obesity and its management in primary care setting
Ibrahim, M. A., Ba-Essa, E. M., Alvarez, J. A., Baker, J. C., Bruni, V., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Domenico, F. D., et al. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109045 · Cited by 21
Self-citationAsplund, O., Thangam, M., Prasad, R. B., Lejonberg, C., Ekström, O., Hakaste, L., Smith, J. G., Rosengren, A. H., Oscarsson, J., Carlsson, B., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00283-9 · Cited by 32
Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity
Ge, D., Foer, D., & Cahill, K. N. (2022) · Pulmonary Therapy · doi:10.1007/s41030-022-00211-x · Cited by 14
Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus
Berg, D. D., Moura, F. A., Bellavia, A., Scirica, B. M., Wiviott, S. D., Bhatt, D. L., Raz, I., Bohula, E. A., Giugliano, R. P., Park, J., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.031 · Cited by 14
N6-methyladenosine RNA modification: an emerging molecule in type 2 diabetes metabolism
Zhang, H., Gu, Y., Gang, Q., Huang, J., Xiao, Q., & Ha, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1166756 · Cited by 20
“Thus, it is the first-line drug for T2D recommended in the latest American Diabetes Association and European Association for the Study of Diabetes consensus (119, 120).”
BackgroundTilinca, M. C. (2023) · FARMACIA · doi:10.31925/farmacia.2023.4.4 · Cited by 22
Guldemond, N. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15476 · Cited by 23
Brierley, M. L., Chater, A., Edwardson, C. L., Castle, E. M., Hunt, E. R., Biddle, S., Sisodia, R., & Bailey, D. P. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01336-6 · Cited by 18
“Reducing daily sedentary time and regularly breaking up prolonged sitting are, therefore, considered important components of 24-hour physical behaviours for T2DM and are recommended for optimal management of this condition [18, 19].”
BackgroundGLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes
Ciardullo, S., Morieri, M. L., DANIELE, G., Fiorentino, T. V., Mezza, T., Tricò, D., Consoli, A., Prato, S. D., Giorgino, F., Piro, S., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02300-6 · Cited by 19
Self-citationSaravanan, P., Bell, H. K., Braae, U. C., Collins, E., Deinega, A., Dhatariya, K., Machell, A., Trent, A., & Strzelecka, A. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02973-z · Cited by 16
“National [2] as well as international [3] guidelines recommend early treatment of T2D for reducing the risk of both microvascular and macrovascular complications.”
BackgroundMethodInfluentialBarnard-Kelly, K. D., Battelino, T., Brosius, F. C., Ceriello, A., Cosentino, F., Gavin, J. R., Giorgino, F., Green, J., Ji, L., Kellerer, M., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02550-2 · Cited by 16
Self-citationHosny, N. M., & Darwısh, I. A. (2025) · Talanta · doi:10.1016/j.talanta.2025.127790 · Cited by 15
Boccardi, V., Bahat, G., Balcı, C., Bourdel‐Marchasson, I., Christiaens, A., Donini, L. M., Çavdar, S., Maggi, S., Özkök, S., Pavić, T., et al. (2025) · European Geriatric Medicine · doi:10.1007/s41999-025-01168-1 · Cited by 21
“Considering such evidence, diabetes care must be individualized due to the highly heterogeneous nature of this population [22, 23].”
Role of the exercise professional in metabolic and bariatric surgery
Stults‐Kolehmainen, M., Bond, D. S., Richardson, L. A., Herring, L. Y., Mulone, B., Garber, C. E., Morton, J. M., Ghiassi, S., Duffy, A. J., Balk, E., et al. (2023) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2023.09.026 · Cited by 19
Qin, Y.-N., & Zheng, X. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01165-z · Cited by 16
“The previous clinical guidelines and consensus report advocate that frailty assessment is an essential component of diabetes management for older patients [48, 49].”
BackgroundBanerjee, M. (2023) · Circulation Heart Failure · doi:10.1161/circheartfailure.123.010966 · Cited by 16
Kushner, P., Anderson, J. E., Simon, J., Boye, K. S., Ranta, K., Torcello-Gómez, A., & Levine, J. A. (2023) · Clinical Diabetes · doi:10.2337/cd22-0029 · Cited by 14
Kacha, G., HIGHTON, P. J., Funnell, M. P., Gillies, C., Onuwe, T., Kumar, N. S., Cos, X., Ceriello, A., Seidu, S., & Khunti, K. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.113001 · Cited by 19
Lean type 2 diabetes: the overlooked epidemic reshaping global health
Singh, V. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02015-w · Cited by 21
Buse, J. B., BAJAJ, H. S., Dalskov, S., Donaldson, L., Duus, H. H. H., Fabricius, T. W., Haluzík, M., Lingvay, I., Pedersen, S. D., Pratley, R. E., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00125-7 · Cited by 22
Self-citationPleiotropic effects of GLP‐1 receptor agonists on peripheral artery disease: Is there any hope?
Caruso, P., Maiorino, M. I., Bellastella, G., Esposito, K., & Giugliano, D. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3627 · Cited by 13
“5,6 Accordingly, the joint consensus released by the American Diabetes Association and the European Association for the Study of Diabetes has recommended both GLP ‐ 1RAs and sodium glucose transporter ‐ 2 inhibitors as the first ‐ line therapy to reduce the cardio ‐ renal risk in people with T2DM.”
MethodInfluentialMartinka, E., Dravecká, I., & Tkáč, I. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01435-z · Cited by 16
Morgan, T. L., Faught, E., Ross‐White, A., Fortier, M., Duggan, M., Jain, R., Lane, K. N., Lorbergs, A. L., Maclaren, K., McFadden, T., et al. (2023) · BMC Family Practice · doi:10.1186/s12875-023-02091-9 · Cited by 18
“This paradigm has been gaining traction nationally and internationally, such as with health guidelines for some chronic diseases [4].”
BackgroundJain, A., Vispute, A., Dange, A., Naskar, A., Mondal, A., Vivekanand, B., Sharma, B., Varade, D., Shukla, D., Bhatia, G., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01504-3 · Cited by 14
Loganathan, C., Ameén, F., Sakayanathan, P., Islam, M. A., & Palvannan, T. (2023) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2023.107996 · Cited by 18
Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01229-0 · Cited by 15
“Type 2 diabetes (T2D) is a worldwide medical problem with increasing mortality and morbidity [1].”
BackgroundLim, L., Hussein, Z. B., Noor, N. M., Raof, A. S. A., Mustafa, N., Bidin, M. B. L., Ghani, R. A., Samsuddin, S., Yong, S.-L., Foo, S. H., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0296298 · Cited by 15
“The uptake of these GDMT may change with the recent updates to consensus guidance that now recommend an SGLT2 inhibitor or GLP1-RA as first or second-line treatment in patients with either high-risk T2D or cardiorenal diseases https://doi.org/10.1371/journal.pone.0296298.g003 [23,24,34,46].”
BackgroundMethodInfluentialEvans, M., Husain, M., Srivastava, A., Mangla, K. K., Kuhlman, A. B., & Lingvay, I. (2024) · Advances in Therapy · doi:10.1007/s12325-023-02750-4 · Cited by 13
“…American Diabetes Association and the European Association for the Study of Diabetes specifically recommend the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) or sodium–glucose cotransporter 2 inhibitors (SGLT2is) [9, 10], irrespective of baseline blood glucose levels or metformin use.”
BackgroundApproach to the Patient With Type 2 Diabetes Requiring Add-On Medication
Baum, H. B. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae056 · Cited by 14
Tan, X., Divino, V. M., Amamoo, J. J., Xie, L., Coyle, K. B., Gamble, C. L., Guevarra, M., Paprocki, Y., & King, A. A. (2024) · Clinical Drug Investigation · doi:10.1007/s40261-024-01354-2 · Cited by 16
“Current guidelines recommend a holistic, multifactorial, individualized treat-ment approach that emphasizes achieving glycemic and weight goals, together with reducing the risk of cardiovascular comorbidities [2, 33].”
Forbes, A., Hinton, W., Feher, M. D., Elson, W. H. D., Ordóñez-Mena, J. M., Joy, M., Fan, X., Banerjee, D., Cole, N. I., Munro, N. M., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae071 · Cited by 12
“Sodium-glucose co-transporter 2 (SGLT2) inhibitors are established glucose-lowering drugs for the treatment of type 2 diabetes (T2D) [1 ].”
Furusawa, S., Nomoto, H., Oba‐Yamamoto, C., Takeuchi, J., Ito, M., Kurihara, H., Aoki, S., Miya, A., Kameda, H., Nakamura, A., et al. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej23-0648 · Cited by 18
Karakasis, P., Koufakis, T., Patoulias, D., Barkas, F., Klisic, A. N., Mitrović, M., Doumas, M. N., Παπάνας, Ν., & Popovic, D. S. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15979 · Cited by 20
Block, C. E. M. D., Peleshok, J. C., Wilding, J. P. H., Kwan, A. Y. M., Rasouli, N., Maldonado, J. M., Wysham, C., Liu, M., Aleppo, G., & Benneyworth, B. D. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01660-0 · Cited by 16
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2023) · Cardiology Research · doi:10.14740/cr1459 · Cited by 14
“In the ADA/EASD consensus report 2022 [13], there is the following description.”
BackgroundMa, J., Liu, M., Wang, R., Du, L., & Ji, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15446 · Cited by 12
“…reduction and, most stringently, HbA1c ≤ 6.5% and ≥ 10% weight reduction represent the Chinese Diabetes Society, 18 American Diabetes Association/European Association for the Study of Diabetes, 3 and American Association of Clinical Endocrinology (AACE) 20 guideline recommendations, respectively.”
BackgroundInfluentialKim, H., Kim, S. R., & Jung, U. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125544 · Cited by 22
STOUGAARD, E. B., Andersen, M. R., Bagger, J. I., Søndergaard, E., Østergaard, J. A., Curovic, V. R., Persson, F., Almdal, T., Mathiesen, A. S., Andries, A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16606 · Cited by 14
“30 Currently, these medications have not been approved for individuals with type 1 diabetes due to a lack of evidence supporting a cardio-renal protective effect in this population.”
Self-citationAl‐Ozairi, E., Irshad, M., Alkandari, J., SOJAN, L. G., Alroudhan, D., Alotaibi, N., & le Roux, C. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70172 · Cited by 14
Gandhi, A., & Parhizgar, A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1708565 · Cited by 18
Naseralallah, L. M. A., & Aboujabal, B. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2181074 · Cited by 18
“However, tirzepatide has not yet been approved for the sole management of obesity [58].”
BackgroundHe, L., Zheng, W., Li, Z., Chen, L., Kong, W., & Zeng, T. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04006-9 · Cited by 195
“However, the current therapeutic strategies for diabetes can only partially prevent complications [4].”
BackgroundOpening the Precision Diabetes Care through Digital Healthcare
Lee, J., Yu, J. S., & Yoon, K. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0386 · Cited by 16
Cersósimo, E., Alatrach, M., Solis‐Herrera, C., Baskoy, G., Adams, J. M., HANSIS-DIARTE, A. A., Gastaldelli, A., Chávez, A. O., Triplitt, C. L., & DeFronzo, R. A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad438 · Cited by 14
Wallach, J. D., Deng, Y., Polley, E. C., Dhruva, S. S., Herrin, J. S., Quinto, K., Gandotra, C., Crown, W. H., Noseworthy, P. A., Yao, X., et al. (2023) · Clinical Trials · doi:10.1177/17407745231193137 · Cited by 16
Nomoto, H., Takahashi, Y., Takano, Y., Yokoyama, H., Tsuchida, K., Nagai, S., Miya, A., Kameda, H., Cho, K. Y., Nakamura, A., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082163 · Cited by 15
“To achieve this goal, both managing metabolic dysfunction and preventing diabetic complications caused by hyperglycemia are required [1,2].”
BackgroundSilva-Tinoco, R., Cuatecontzi-Xochitiotzi, T., Castillo‐Martínez, L., de la Torre-Saldaña, V., GUZMAN-OLVERA, E. B., & Bernal-Ceballos, F. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.07.004 · Cited by 14
Kokkorakis, M., Folkertsma, P., van Dam, S., Sirotin, N., Taheri, S., Chagoury, O. L., Idaghdour, Y., Henning, R. H., Forte, J. C., Mantzoros, C. S., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102235 · Cited by 15
The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus
Giorgino, F., Battelino, T., Bergenstal, R. M., Forst, T. M., Green, J. B., Mathieu, C., Rodbard, H. W., Schnell, O., & Wilmot, E. G. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231204584 · Cited by 20
“46”
Self-citationAbid, S., Sial, N., Hanif, M., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23452 · Cited by 12
“An estimated 422 million people worldwide are thought to have diabetes mellitus as a result of an increase in the disease ’ s prevalence over the past few years [2].”
BackgroundRetractedSzafranski, K., de Pouvourville, G., Greenberg, D., Harris, S. B., JENDLE, J. H., Shaw, J. E., Coaquira, J., Poon, Y., & Levrat‐Guillen, F. (2024) · Value in Health · doi:10.1016/j.jval.2024.01.010 · Cited by 16
Narrative review of data supporting alternate first-line therapies over metformin in type 2 diabetes
Andraos, J., Smith, S. R., Tran, A., & Pham, D. Q. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01406-6 · Cited by 20
“Metformin has been shown metformin as the only first-line therapy and provided the emphasis of using GLP-1 RA or SGLT-2i as first line options in patients with cardiovascular and renal disease [7].”
BackgroundAlshaya, O. A., Korayem, G. B., Alghwainm, M., Alyami, W., Alotaibi, A., Yami, M. S. A., & Almohammed, O. A. (2024) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2024.102054 · Cited by 17
“These updates emphasize the utilization of SGLT2i and GLP-1 RA as first-line therapy for patients at high risk or with established ASCVD, HF, CKD, and obesity (Davies et al., 2022, de Boer et al., 2022).”
BackgroundSuzuki, R., Amadid, H., Major‐Pedersen, A., & Yabe, D. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14219 · Cited by 12
Alshaikh, A. A., Al-Qahtani, F. S., Taresh, H. M. N., Hayaza, R. A. A., Alqhtani, S. S. M., Summan, S. I., Mansour, S. A. A., Alsultan, O. H. A., Asiri, H. Y. M., Alqahtani, Y. M. S., et al. (2024) · Medicina · doi:10.3390/medicina60050775 · Cited by 15
“IDF emphasizes lifestyle modifications such as increased physical activity and the adoption of a healthy diet as effective measures to prevent or delay the onset of DM2 [6].”
BackgroundPeters, A. L., Buzzetti, R., Lee, C. J., Pavo, I. J., Liu, M., Karanikas, C. A., & Paik, J. S. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae372 · Cited by 18
Janota, O., Mantovani, M., Kwiendacz, H., Irlik, K., Bucci, T., Lam, S. H. M., Huang, B., Alam, U., Boriani, G., Hendel, M., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02420-x · Cited by 15
Widiarti, W., Saputra, P. B. T., Savitri, C. G., Putranto, J. N. E., & Alkaff, F. F. (2024) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2024.09.007 · Cited by 20
Zhang, Q., Xiao, S., Zou, F., Jiao, X., & Shen, Y. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101616 · Cited by 16
Tirzepatide for type 2 diabetes
Anderson, S. L., & Marrs, J. C. (2023) · Drugs in Context · doi:10.7573/dic.2023-6-1 · Cited by 21
Technology to overcome therapeutic inertia
Greenwood, D. A., & Peeples, M. (2019) · mHealth · doi:10.21037/mhealth.2018.12.05 · Cited by 13
Rico-Fontalvo, J. E., Daza-Arnedo, R., Cardona-Blanco, M., Leal-Martínez, V., Abuabara-Franco, E., Pájaro-Galvis, N., Cabrales, J., Correa, J., Cueto, M., Amable, D., et al. (2020) · Journal of Clinical Nephrology · doi:10.29328/journal.jcn.1001058 · Cited by 14
Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
Viljoen, A., & Bain, S. C. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1642 · Cited by 11
Castellino, L. M., Crisologo, P. A., Chhabra, A. B., & Öz, O. K. (2025) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2025.02.014 · Cited by 22
He, Y., Mi, N., Cheng, Z., Xue, H., Han, J., Wang, H., Wang, H. H., Wu, J., Shi, X., Zhao, S., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00196-2 · Cited by 15
From Diabetes to Degenerative Diseases: The Multifaceted Action of Metformin
Campagnoli, L. I. M., Varesi, A., Fahmideh, F., Hakimizad, R., Petkovic, P., Barbieri, A., Marchesi, N., & Pascale, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199748 · Cited by 16
“Metformin is used either as monotherapy or in combination with other hypoglycemic agents such as sulfonylureas, dipeptidyl peptidase-4 inhibitors, sodium-glucose transport protein-2 inhibitors, and insulin, which exerts synergistic effects [5,32–38].”
Tartaglia, E., Bucci, T., Rossi, M., Rigutini, A. G., Askarinejad, A., Alam, U., Nabrdalik, K., Boriani, G., & Lip, G. Y. H. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02986-0 · Cited by 22
“In T2DM, they are typically recommended as second-line or add-on therapy—most often after metformin fail-ure—and more recently as first-line agents in people with established cardiovascular or renal disease [15, 16].”
Metadata
- Authors
- Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B.
- Affiliations
- University of Leicester (GB)
- Brigham and Women's Hospital (US)
- National Heart, Lung, and Blood Institute (US)
- American Diabetes Association (US)
- Duke University (US)
- Johns Hopkins University (US)
- Joslin Diabetes Center (US)
- 9Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- KU Leuven (BE)
- Università Cattolica del Sacro Cuore (IT)
- University of Copenhagen (DK)
- Medical University of Sofia (BG)
- 17Diabetes Centre, Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-09-28
- Volume
- 45
- Issue
- 11
- Pages
- 2753-2786
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC10008140
- OpenAlex
- W4296802076
- Cited by
- 2,104
- References
- 348
- Citations by year
- 2026: 500 · 2025: 567 · 2024: 509 · 2023: 396 · 2022: 50
- FWCI
- 282.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- European Association for the Study of Diabetes
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, glycemic targets, social determinants of health, physical activity, sleep, weight management, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, cardiovascular outcomes, renal outcomes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Europe, Humans, Hyperglycemia, Hypoglycemic Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.